The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors. EPO signalling involves tyrosine phosphorylation of the homodimeric EPO receptor and subsequent activation on intracellular proteins, kinases and transcription factors. Treatment with erythropoietic stimulating agents (ESA) or ecombinant human EPO (rHuEPO) is efficient and safe in improving the management of the anaemia associated with chronic kidney disease, and allowing avoidance of transfusions with blood products. However, the unanticipated increase in mortality found in recent randomized studies is prompting a reassessment of this view. The present review will show what is known about the physiology of this plasma factor that, it is now clear, is more than just an erythrocyte production factor, and its pleitropic effects influencing the incidence of malignancy, thrombosis, hypertension and retinopathy.
|Translated title of the contribution||The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, thrombosis and hypertension: Beyond anaemia|
|Number of pages||7|
|State||Published - Dec 31 2009|
- Erythropoietic stimulating agent
- Recombinant human erythropoietin
ASJC Scopus subject areas